agradam
Agradam is a synthetic opioid analgesic that was developed in the 1960s. It is a centrally acting opioid that acts primarily on mu-opioid receptors in the brain. Agradam is a prodrug, meaning it is inactive until it is metabolized in the body. Once metabolized, it is converted into its active metabolite, 3-methylmorphinan-6-ol (3-MMO), which is a potent mu-opioid receptor agonist.
The drug was initially developed for use as a pain reliever, but its development was halted due
Despite its discontinuation, Agradam has gained attention in the context of illicit drug use. It is sometimes
Agradam is a Schedule I controlled substance in the United States, meaning it is considered to have
The exact chemical structure of Agradam is not widely known, as it was never approved for medical
The use of Agradam is associated with a high risk of dependence and addiction. Users may experience
In summary, Agradam is a synthetic opioid analgesic that was never approved for medical use due to